Scienza e Tecnologia
Notice of First Quarter 2023 Results
Dial in details for the presentation are detailed below.
https://webcast.openbriefing.com/pharming1q23/
Netherlands : +31 85 888 7233
United Kingdom (Local): +44 20 3936 2999
United Kingdom (Toll-Free): +44 808 189 0158
United States (Local): +1 646 664 1960
United States (Toll-Free): +1 855 979 6654
Global Dial-In Numbers
Access Code: 598957
Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules, biologics, and gene therapies that are in early to late-stage development. Pharming is headquartered in Leiden,
Netherlands , and has employees around the globe who serve patients in over 30 markets in
North America , Europe , the
Middle East , Africa , and
Asia-Pacific .
For more information, visit www.pharming.com and find us on LinkedIn.
Michael Levitan, VP Investor Relations & Corporate Communications
T: +1 (908) 705 1696
Heather Robertson , Investor Relations & Corporate Communications Manager
E: investor@pharming.com
Victoria Foster Mitchell / Alex Shaw /Amy Byrne
T: +44 203 727 1000
Leon Melens
T: +31 6 53 81 64 27 E: pharming@lifespring.nl
Logo: https://mma.prnewswire.com/media/2003587/Pharming_Group_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/notice-of-first-quarter-2023-results-301801417.html